# Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

> **NCT03082833** · PHASE2 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Cancer of Stomach

## Interventions

- **DRUG:** AZD2014

## Key facts

- **NCT ID:** NCT03082833
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-11-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082833, "Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03082833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*